PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy

Gynecologic Oncology

Volumn 128, Issue 3, 2013, Pages 409-414

  McIntyre, John B ^a   Wu, Jackson S ^a   Craighead, Peter S ^a   Phan, Tien ^a   Köbel, Martin ^a   Lees Miller, Susan P ^a,b   Ghatage, Prafull ^a   Magliocco, Anthony M ^c   Doll, Corinne M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cervical cancer; Chemoradiotherapy; PIK3CA; Survival

Indexed keywords

CISPLATIN; GENOMIC DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CA PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; DNA EXTRACTION; EXON; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84873719544     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.12.019     Document Type: Article

References (27)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials J Clin Oncol 26 2008 5802 5812
3. J.A. Green, J.J. Kirwan, J. Tierney, C.L. Vale, P.R. Symonds, and L.L. Fresco Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix (review) Cochrane Gynaecological Cancer Group Cochrane Database of Systematic Reviews 2 2012
4. R. Ashfaq Molecular profiling for personalized cancer care Clin Exp Metastasis 29 2012 653 655
5. F.S. Ong, K. Das, J. Wang, H. Vakil, J.Z. Kuo, and W.L. Blackwell Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing Expert Rev Mol Diagn 12 2012 593 602
6. B.T. Hennessy, D.L. Smith, P.T. Ram, Y. Lu, and G.B. Mills Exploiting the PI3K/AKT pathway for cancer drug discovery Nat Rev Drug Discov 4 2005 988 1004
7. B. Karakas, K.E. Bachman, and B.H. Park Mutation of the PIK3CA oncogene in human cancers Br J Cancer 94 2006 455 459
8. G. Ligresti, L. Militello, L.S. Steelman, A. Cavallaro, F. Basile, and F. Nicoletti PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches Cell Cycle 8 2009 1352 1358
9. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, and S. Szabo High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554
10. K. Oda, D. Stokoe, Y. Taketani, and F. McCormick High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma Cancer Res 65 2005 10669 10673
11. M.P. Hayes, H. Wang, R. Espinal-Witter, W. Douglas, G.J. Solomon, and S.J. Baker PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia Clin Cancer Res 12 2006 5932 5935
12. D.A. Levine, F. Bogomolniy, C.J. Yee, A. Lash, R.R. Barakat, and P.I. Borgen Frequent mutation of the PIK3CA gene in ovarian and breast cancers Clin Cancer Res 11 2005 2875 2878
13. K.E. Bachman, P. Argani, Y. Samuels, N. Silliman, J. Ptak, and S. Szabo The PIK3CA gene is mutated with high frequency in human breast cancers Cancer Biol Ther 3 2004 772 775
14. I.G. Campbell, S.E. Russell, D.Y. Choong, K.G. Montgomery, M.L. Ciavarella, and C.S. Hooi Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Res 64 2004 7678 7681
15. Y. Samuels, and K. Ericson Oncogenic PI3K and its role in cancer Curr Opin Oncol 18 2006 77 82
16. T. Miyake, K. Yoshino, T. Enomoto, T. Takata, H. Ugaki, and A. Kim PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences Cancer Lett 261 2008 120 126
17. F. Janku, A.M. Tsimberidou, I. Garrido-Laguna, X. Wang, R. Luthra, and D.S. Hong PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors Mol Cancer Ther 10 2011 558 565
18. F. Janku, J.J. Lee, A.M. Tsimberidou, D.S. Hong, A. Naing, and G.S. Falchook PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers PLoS One 6 2011 e22769
19. N.T. Ihle, R. Lemos Jr., P. Wipf, A. Yacoub, C. Mitchell, and D. Siwak Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance Cancer Res 69 2009 143 150
20. F. Janku, J.J. Wheler, S.N. Westin, S.L. Moulder, A. Naing, and A.M. Tsimberidou PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations J Clin Oncol 30 2012 777 782
21. W. Qiu, F. Schonleben, X. Li, D.J. Ho, L.G. Close, and S. Manolidis PIK3CA mutations in head and neck squamous cell carcinoma Clin Cancer Res 12 2006 1441 1446
22. C.I. Muller, C.W. Miller, W.K. Hofmann, M.E. Gross, C.S. Walsh, and N. Kawamata Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene Leuk Res 31 2007 27 32
23. L.C. Silva-Aycaguer, P. Suarez-Gil, and A. Fernandez-Somoano The null hypothesis significance test in health sciences research (1995-2006): statistical analysis and interpretation BMC Med Res Methodol 10 2010 44
24. B. Cui, B. Zheng, X. Zhang, U. Stendahl, S. Andersson, and K.L. Wallin Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women Int J Oncol 34 2009 409 416
25. S. Lee, E.J. Choi, C. Jin, and D.H. Kim Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line Gynecol Oncol 97 2005 26 34
26. J.K. Schwarz, J.E. Payton, R. Rashmi, T. Xiang, Y. Jia, and P. Huettner Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer Clin Cancer Res 18 2012 1464 1471
27. E. Fokas, J.H. Im, S. Hill, S. Yameen, M. Stratford, and J. Beech Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature Cancer Res 72 2012 239 248